Penserra Capital Management LLC I Mab Transaction History

Penserra Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$45.28 - $74.5 $43,468 - $71,520	-960 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $13,437 - $19,841	235 Added 32.41%	960 $69,000
Q2 2021 Aug 12, 2021	BUY	$47.86 - $83.95 $14,597 - $25,604	305 Added 72.62%	725 $60,000
Q1 2021 May 13, 2021	BUY	$44.38 - $63.97 $2,662 - $3,838	60 Added 16.67%	420 $20,000
Q4 2020 Feb 12, 2021	BUY	$32.94 - $47.15 $11,858 - $16,974	360 New	360 $16,000

16.4M

1.9K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $108M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.